Skip to main content

CITADEL ADVISORS LLC

Position in ENGN — enGene Therapeutics Inc.

CIK 1423053 MIAMI, FL

Position in ENGN

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$1,241,596
+$193,251 QoQ
Shares Held
717,686
+366.2% QoQ
Ownership
1.07%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#16
of 60 holders
Holding Since
Dec 2023
8 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in ENGN Over Time

Shares Held

Position Value (USD)

Derivatives in ENGN

reported options exposure · as of Jun 30, 2026
CallValue
$53,284
CallShares
30,800
PutValue
$56,744
PutShares
32,800

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

CITADEL ADVISORS LLC holds $6,088,670,159 across 436 Biotechnology names. ENGN ranks #217 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in ENGN

Export CSV
10 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $1,241,596 717,686
2026-06-30 $56,744 32,800
2026-06-30 $53,284 30,800
2026-03-31 $1,048,345 153,942
2025-12-31 $229,208 25,383
2025-09-30 $398,667 58,370
2025-06-30 $83,876 23,043
2024-06-30 $5,783,343 613,292
2024-03-31 $13,630,816 804,178
2023-12-31 $185,126 20,057